What are the current recommendations for peri‑operative management of rivaroxaban (Xarelto) in patients undergoing hip hemiarthroplasty?

Perioperative Management of Rivaroxaban (Xarelto) for Hip Hemiarthroplasty

For hip hemiarthroplasty, stop rivaroxaban 2 days (48 hours) before surgery, do not use bridging anticoagulation, and resume rivaroxaban 24-72 hours postoperatively once surgical hemostasis is achieved.

Preoperative Management

Hip hemiarthroplasty is classified as a high-bleed-risk procedure, which dictates the timing of rivaroxaban interruption 1.

Timing of Discontinuation

• Stop rivaroxaban 2 days before surgery (last dose 48 hours prior to incision) 1
• This applies regardless of whether the patient is taking rivaroxaban for atrial fibrillation or VTE treatment/prevention 1
• The 2-day interruption assumes normal renal function (CrCl ≥ 50 mL/min) 1

Important caveat: The French GIHP guidelines recommend a 3-day interruption for rivaroxaban before high-bleeding-risk procedures 2, which is slightly more conservative than the 2022 CHEST guidelines. Given that hip hemiarthroplasty carries substantial bleeding risk and often involves elderly patients with potential renal impairment, the 3-day approach may be safer in clinical practice.

Practical Dosing Schedule

• Once-daily dosing (morning): Last dose 3 mornings before surgery (e.g., if surgery is Thursday morning, last dose is Monday morning) 2
• Once-daily dosing (evening): Last dose 3 evenings before surgery 2
• Twice-daily dosing: Last dose on the morning 2 days before surgery 2

No Bridging Required

Do not use heparin bridging (neither UFH nor LMWH) during the interruption period 1, 2. The evidence is clear:

• Perioperative LMWH bridging increases major bleeding risk threefold (4.8% vs 1.6%) without reducing thromboembolic events 1
• The rapid offset and onset of DOACs eliminate the need for bridging 1
• Exception: Only consider bridging in patients at very high thrombotic risk (not routinely applicable to most hip fracture patients) 2

No Routine Laboratory Monitoring

• Do not routinely measure rivaroxaban levels before surgery if the recommended interruption period is followed 2
• Laboratory monitoring may be considered only for very high-bleeding-risk scenarios (e.g., neuraxial anesthesia in elderly patients with renal impairment) 2

Postoperative Management

Timing of Resumption

Resume rivaroxaban 24-72 hours after surgery once adequate surgical hemostasis is achieved 1, 2. The specific timing depends on:

• Bleeding risk assessment: If hemostasis is secure and no ongoing bleeding, can resume at 24 hours
• Surgical considerations: Consult with the surgical team regarding wound status
• Patient factors: Assess for any bleeding complications

Bridging Postoperatively

• Use prophylactic-dose LMWH or fondaparinux starting ≥6 hours postoperatively until rivaroxaban is resumed 2
• This provides VTE prophylaxis during the gap period before therapeutic anticoagulation resumes
• Do not overlap LMWH and rivaroxaban—give the first therapeutic dose of rivaroxaban 12 hours after the last prophylactic LMWH dose 2

Special Consideration for Neuraxial Anesthesia

If an epidural catheter is in place:

• Do not resume therapeutic-dose rivaroxaban while the catheter is present 2
• Use prophylactic heparin instead until the catheter is safely removed
• Only resume therapeutic rivaroxaban after catheter removal per established neuraxial guidelines 2

Key Clinical Pitfalls to Avoid

1. Renal function: Always check recent creatinine clearance—if CrCl < 50 mL/min, consider extending the preoperative interruption period 2

2. Drug interactions: Check for P-glycoprotein or CYP3A4 inhibitors that increase rivaroxaban levels (e.g., ketoconazole, ritonavir)—these may require longer interruption 2

3. Age considerations: Elderly hip fracture patients often have reduced renal function—don't assume normal clearance 2

4. Timing errors: Ensure clear communication about "days off"—2 days means 48 hours, not skipping 2 doses 1

5. Premature resumption: Resist pressure to resume anticoagulation early if surgical hemostasis is questionable—bleeding complications significantly outweigh short-term VTE risk 1

Evidence Quality Note

The 2022 CHEST guidelines 1 represent the most recent and authoritative guidance, though they are based primarily on observational data and subgroup analyses rather than randomized trials specific to hip hemiarthroplasty. The French GIHP guidelines 2 provide more conservative recommendations that may be preferable in high-risk elderly populations typical of hip fracture surgery.